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Background: COPD patients are susceptible to anorexia, reduction of caloric intake, weight loss, 
and malnutrition. One of the possible mechanisms is the increase of inflammatory markers such 
as interleukin 1β (IL
1β), is highly correlated with anorexia. Considering the anti-inflammatory 
role of conjugated linoleic acid (CLA), this study aimed to investigate the effect of CLA 
supplementation on the nutritional status of COPD patients.
Patients and methods: In a double-blind clinical trial, 93 COPD patients who volunteered 
to participate in the study and who filled out a written consent form, were randomly assigned 
to control or supplementation groups. The patients in the supplementation group received 
3.2 g of CLA on a daily basis for 6 weeks, while those in the control group received placebo 
on a daily basis for 6 weeks. For IL
1β assessment, the patients’ anthropometric indices and 
appetite score were checked and their blood samples were collected both before and after 
the treatment. Moreover, in order to investigate the changes in the caloric intake trend dur-
ing the study, their dietary intake levels were assessed using 24-hour dietary recall, 3 days 
a week at the onset, in the 4th week, and at the end of the study. Eventually, 90 patients 
completed the study.
Results: The results demonstrated a significant increase in appetite score (P=0.001), average 
caloric intake (P=0.01), and macronutrient intake (P,0.05), while a significant decrease was 
observed in the serum level of IL
1β among the patients of the supplementation group (P=0.008). 
Meanwhile, although the supplementation group’s body mass index was also higher on comple-
tion, compared to their own initial state as well as to that in the control group, the differences 
were not significant (P=0.13).
Conclusion: The findings of this research indicate that the consumption of CLA supplementa-
tion can be effective in regulating the appetite and improving the nutritional status of patients 
suffering from COPD through adjusting the serum level of IL
1β.
Keywords: COPD, CLA, appetite, nutritional status, IL
1β
Introduction
COPD is a common respiratory condition, which occurs with pulmonary and 
extrapulmonary complications, accompanied by systemic inflammations and is charac-
terized by irreversible airflow limitations.1 It has been predicted that by 2020, it would 
be the third most common cause of death and the fifth most common cause of disability 
worldwide.2 Smoking and factors such as contamination of the workplace, environ-
mental pollution, and genetics are found to be the main causes of this disease.3,4
Extrapulmonary complications that occur in COPD patients are appetite reduction, 
decrease of caloric intake, and malnutrition.5 Malnutrition leads to increased risks of 
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mortality among these patients.6 The increase of inflammatory 
factors such as serum level of C-reactive protein7 and inflam-
matory interleukins (ILs) such as IL
1β, IL6, and also tumor 
necrosis factor-α has been found to be among the possible 
causes of malnutrition.8 In various studies, the increase in 
the serum level of ILs such as IL
1β and IL6 as well as tumor 
necrosis factor-α has been reported in these patients.9–11 The 
increase of IL
1β strongly causes anorexia, increased energy 
consumption, loss of muscle protein, and leptin release of 
adipose cells, which, in turn, lead to malnutrition.12,13
The use of dietary supplements is usually recommended 
for the treatment of malnutrition after COPD diagnosis, and 
it has been reported that the nutritional supplementations 
can improve nutritional status, anthropometric factors, and 
body weight,14,15 reduce disease symptoms,16 and improve 
quality of life.17
One of the supplements used along with treatment is 
conjugated linoleic acid (CLA; polyunsaturated fatty acid), 
which is naturally found in animal sources.18 In recent years, 
increasing attention has been paid to the beneficial effects 
of CLA on individuals’ health status.19 To mention a few 
findings, researchers have discovered that it improves food 
sufficiency, energy metabolism,20 and anti-inflammatory 
properties.21 The effect of CLA on some of the inflammatory 
factors has been demonstrated in previous studies;21 however, 
scant studies have examined its effect on the nutritional status 
and caloric intake of COPD patients. Therefore, this study 
aimed to evaluate the effects of CLA supplementation on the 
nutritional status of COPD patients.
Patients and methods
study design and population
Ninety-three male COPD patients were studied in a double-
blind clinical trial at the pulmonary ward of the Imam 
Khomeini Hospital in Ardabil in April–December 2015. 
To do so, the patients suffering from COPD were selected 
based on the American Thoracic Society criteria.22 The 
selected patients had chronic cough, sputum production, 
and dyspnea with the spirometry results of forced expiratory 
volume at first second/forced vital capacity ratio ,70%, and 
their age range was 40–80 years. The COPD patients suf-
fering from other chronic diseases such as cardiovascular 
diseases, diabetes, and malignancies were excluded from 
the study. Before the study, all the participants signed an 
informed consent and completed a reliable and validated 
questionnaire, which was designed to gather anthropometric 
and demographic information. The information obtained 
through the questionnaires contained each participant’s 
name, age, literacy level, job, address, history of smoking and 
quitting it, and the number of exacerbations experienced in 
the previous year. Eventually, 90 patients accomplished the 
study (45 patients in each of the placebo and supplementa-
tion groups) (Figure 1).
This study was ratified in the research department of Ardabil 
University of Medical Sciences (Iran) with the ethical code 
of “Arums.REC.93.56” and registered in Iranian Registry of 
Clinical Trial with the code of “IRCT2015080823559N1”.
anthropometric information
The patients’ weight and height indices were recorded, and 
their body mass indices (BMIs) were obtained by calculating 
the ratio of their weight (kg) to their height squared (m2) 
at the beginning and at the sixth week of the study. The 
individuals’ fasting weights were measured with the accu-
racy of 0.1 kg using Seca scales while they were without 
shoes and had light clothes on. Each time at certain stages, 
accuracy and precision of the Seca scales were calibrated 
using a standard 5 kg weight. Moreover, the height of the 
participants was measured by a graded wall. To do so, a 
measuring tape was installed on the wall. The participants 
stood upright while their heels, buttocks, shoulders, and 
heads leaned on the wall. Then, by placing a ruler hori-
zontally on their head, their height was measured with the 
accuracy of 1 cm.
nutritional information
The patients’ nutritional intake levels were assessed using 
a 24-hour dietary recall 3 days a week (2 weekdays and 
1 weekend day) at the beginning, at the 4th week, and at the 
6th week of the study (nine times in total). The content of 
the nutrients (macronutrients and micronutrients) and the 
energy intake of the patients were measured and analyzed 
by the Nutritionist IV software. A standard form was used to 
determine the appetite score of the participants at the begin-
ning, at the fourth week, and at the sixth week of the study.
Biochemical information
Information on biochemical parameters of the patients’ 
blood: 3 cc of venous blood sample was taken from each of 
the patients with 12 hours of fasting at the beginning and at 
the end of the study. The samples were gently transferred 
to test tubes, labeled, and then taken to a laboratory for 
serum separation. They were centrifuged at 4,000 rpm for 
5 minutes and then poured into microtubes for IL
1β test. 
The tubes were transferred to a refrigerator with the tem-
perature of -80°C. IL
1β was measured with enzyme-linked 
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immunosorbent assay (ELISA) method using a kit pro-
duced by the German company of Zelbio. According to 
the instructions of the manufacturer of the kit, IL
1β was 
diluted one in ten. In order to increase the accuracy of the 
results, double samples were analyzed in 96-well ELISA 
plates using the standard protocol. Then, the colors formed 
at the frequencies of 450 nm and 630 nm were identified 
by “Anhos 2000 microplate reader”, and the concentration 
of the blood samples was calculated by Multicalc (Wallac, 
Turku, Finland) software.
supplementation
The supplementation group received a daily amount of 3.2 g 
CLA soft gel (with 80% purity, which includes c9-t11 and 
c12-t10 isomers (50/50) and is manufactured in the form 
of tablets in the US with the commercial name of Nutrex), 
while the control group received the same amount of placebo 
for 6 weeks. Before the beginning of the study, the boxes 
containing CLA and placebo were coded as A and B, so that 
the researchers and the patients cannot identify the kind of 
supplementation offered to each group and so that the study 
can be conducted in a double-blinded manner.
Patients’ follow-up
During the study, the patients were called every week to 
obviate any problems that might arise for them as well as to 
ensure that they take the supplementation. In order to both 
control the consumption of supplementation and prevent the 
loss of samples, the follow-up was also done through face-
to-face visits, in addition to making telephone calls. The pills 
needed for 6 weeks were distributed to the patients and they 
were reminded that they should return the rest of the pills if 
they stop consuming them. Ninety-six percent of the patients 
took the pills regularly and were, therefore, investigated 
during the study. The patients’ compliance with the consump-
tion of the pills was evaluated by the remaining pills at the 
end of the sixth week. The patients were informed about the 













Figure 1 The effect of CLA supplementation on the nutritional status of COPD patients flow diagram.
Abbreviation: Cla, conjugated linoleic acid.





of the researcher was given to them to report any problems 
they might encounter during the study.
Data analysis
Kolmogorov–Smirnov test was employed to investigate the 
normality of the distribution of data for each variable. The 
results obtained from them were analyzed by SPSS V11 
software, and t-test, chi-square test, and analysis of vari-
ance were employed to determine the relationship between 
the variables. Significance level was taken to be 0.05 for all 
the tests. In addition, wherever possible, the results were 
expressed in the form of deviations (±) from the mean.
Results
There was no significant difference between the two groups in 
terms of their average age, smoking history, forced expiratory 
volume at first second (Table 1), weight, height, and BMI 
at the beginning of the study (Table 2). Paired t-test showed 
that the average BMI of the patients in the supplementation 
group increased during the study, but it was not statistically 
significant (P=0.13).
The results showed that, at the beginning of the study, 
there was no significant difference between the two groups 
in their serum level of IL
1β; however, at the end of the study, 
the difference appeared to be significant (P=0.02). Paired 
t-test revealed that in the supplementation group, the serum 
level of IL
1β decreased significantly in the sixth week com-
pared to the beginning of the study (P=0.008), while in the 
placebo group, it increased significantly during the same 
time (P=0.02; Table 3).
According to the results, at the beginning of the study, 
there was not any significant difference between the patients 
of the two groups in their appetite score and the average 
caloric intake. Yet, this difference was found to be statistically 
significant at the end of the study as the results of independent 
t-test revealed (P,0.05).
Furthermore, the analyses showed that although the 
difference in the appetite score of the patients in the 
supplementation group was not significant in the fourth week 
(P=0.07), it was significant in the sixth week (P=0.001) as 
compared to the beginning of the study. As for the placebo 
group, the overall changes throughout the study were not 
found to be statistically significant (P=0.06; Figure 2).
In addition, repeated measures analysis of variance dem-
onstrated a significant increase in the average caloric intake 
of the patients in the supplementation group during the study 
(P=0.01). As regards this variable, the difference observed 
between the fourth week and the beginning of the study was 
not significant (P=0.06), while the difference between the 
end of the sixth week and the beginning of the study as well 
as between the end of the sixth week and the fourth week 
appeared to be significant (P,0.05). In the placebo group, 
the average changes throughout the study were not found to 
be statistically significant (Figure 3).
The results revealed that the average amount of carbo-
hydrate, protein, fat, fatty acids (saturated, unsaturated with 
one double bond, and polyunsaturated), cholesterol, and fiber 
intake was not significantly different between the two groups 
at the beginning of the study, but, at the end of the study, 
the results of independent t-test revealed that the difference 
between carbohydrate, protein, fat, fatty acids (saturated, 
unsaturated with one double bond, and polyunsaturated), 
cholesterol, and fiber intake is significant (P,0.05).
In addition, repeated measures analysis of variance dem-
onstrated a significant increase in the average carbohydrate, 
protein, and fat intake (P,0.05) in the supplementation group 
during the study; the changes observed during the study in 
the average intake of fatty acids (saturated, unsaturated with 
one double bond, and polyunsaturated), cholesterol, and 
fiber were not significant. In the placebo group, the trend in 
carbohydrate and protein intake showed significant decrease 
during the study (P,0.05; Table 4).
For both the groups under study, the analysis through 
post hoc least significant difference test did not show any 
significant differences in the average fatty acids (saturated, 
unsaturated with one double bond, and polyunsaturated), 
cholesterol, and fiber intake neither in the fourth week nor 
in the sixth week compared to the beginning of the study. 
Similarly, in the placebo group, the decrease in the intake of 
these during the study was not significant (Table 4).
Regarding the average serum electrolytes intake, the results 
did not show any significant difference between the 
two groups at the beginning of the study. In addition, at 
the end of the study, significant differences between the 
two groups were only observed in the average calcium, 
potassium, and selenium intake (P=0.04; Table 5).
Table 1 Demographic and clinical parameters of lung function 
in the supplementation and placebo groups





Values (n=45) Values (n=45)
age (years) 63.60±10.94 61.64±10.60 0.39
smoking (packs/year) 42.80±23.84 44.89±25.43 0.68
FeV1% predicted 47.83±18.01 42.89±14.82 0.06
Notes: The data are presented as mean ± sD. aIndependent-sample t-test significant 
difference between groups.
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Based on the obtained results, there was no significant 
difference between the two groups in their average vitamin 
intake at the beginning of the study. Furthermore, at the end 
of the study, significant differences between them were only 
observed in vitamins B2, B6, and E intake (P,0.05). In addi-
tion, in the supplementation group, only average vitamins 
B2, B6, and E intake increased significantly during the study 
(P=0.02; Table 6).
Discussion
Studies investigating the effect of CLA on COPD patients are 
scant. To the best knowledge of the researchers, this study 
is the first one addressing this issue. As for other diseases, 
a number of studies have been conducted investigating the 
effect of this supplement on healthy people, chronic diseases, 
and different types of cancers some of which are discussed 
briefly later.
This study demonstrated that the consumption of CLA 
reduces the serum level of IL
1β in COPD patients. Several 
other studies have shown that some cytokines such as serum 
IL
1β increase in these patients.
9,11
Sapey et al23 indicated that the serum level of IL
1β is 
strongly related to COPD disease severity. Hammad et al24 
found that there is a strong significant relationship between 
COPD severity and serum level of IL
1β, which shows that 
it plays an important role in the process of systemic inflam-
mation experienced by the COPD patients. In their case–
control study, Hegab et al25 found that the serum level of 
IL
1β in COPD patients is considerably higher than that in 
the healthy people, which indicates that IL
1β is involved in 
the pathogenesis of COPD. In their study, DeBoer et al26 
injected IL
1β into mice and observed that after 3–12 hours, 
nutritional intake significantly decreased. Therefore, they 
concluded that IL
1β is one of the important mediators in 
this process. It is one of the pre-inflammatory cytokines, 
which is produced from activated macrophages, and is one 
of the important mediators of inflammatory response, which 
causes expression and demonstration of many genes.13,26 The 
increase of this inflammatory mediator in COPD patients 
causes appetite reduction, which contributes to weight loss, 
and reduction of BMI, which, in turn, leads to increased 
risks of malnutrition.12,27 CLA supplementation with differ-
ent isomer percentages and sometimes a relatively special 
isomer is considered as an agent that is antioxidant, anti-
inflammatory, anti-obesity, anticancer, anti-atherosclerosis, 
stimulator of immune system, stimulator of growth factor, 
changer of body composition from fat to muscle, etc, in 
animal and human models.28,29 With its anti-inflammatory 
properties, it can also inhibit inflammatory mediators such 
as IL
1β and decrease their serum level and, thereby, lead to 
appetite improvement in patients.18,20
The findings of this study are in line with those of the 
study of Wendell et al.30 They showed that long-term con-
sumption of CLA could reduce inflammatory mediators such 
as IL
1β, which exacerbate disease, though it should be noted 
that their study was conducted on asthma patients.
Table 2 The average amount of weight, height, and BMI in supplementation and control groups
Variables Measurement stage Supplementation group (n=45) Placebo group (n=45) P-valuea
Weight (kg) at baseline 67±4.6 68.33±4.3 0.42
On completion 67.18±3.3 68±3.7 0.25
P-valueb 0.07 0.07
BMI (kg/m2) at baseline 24.91±3.54 24.84±2.96 0.42
On completion 24.97±3.34 24.74±3.06 0.25
P-valueb 0.13 0.2
height (cm) at baseline 164.13±10 166±8 0.46
Notes: aIndependent-sample t-test significant difference in the 6th week between groups. bPaired t-test significant difference at the beginning and the end of the study in each 
group. Data are presented as mean ± sD.
Abbreviations: BMI, body mass index; sD, standard deviation.
Table 3 The average amount of Il1β serum level in the supplementation and control groups
Variables Measurement stage Supplementation group (n=45) Placebo group (n=45) P-valuea
Il1β (ng/ml) at the beginning 6.38±1.95 6.27±1.02 0.72
at the end 5.61±0.93 6.60±1.07 0.02a
P-valueb 0.008b 0.025b
Notes: aIndependent-sample t-test significant difference in the sixth week between groups. bPaired t-test significant difference at the beginning and the end of the study in 
each group. Data are presented as mean ± sD. 
Abbreviations: Il1β, interleukin 1β; sD, standard deviation.


















Figure 2 Charts demonstrating the trend of CnaQ score37 changes during the 
study in supplementation and control groups.
Note: Patient’s appetite scores at the beginning (blue), 4th week (green), and 
6th week (milky) chart.
Abbreviation: CnaQ, Council of nutrition appetite Questionnaire.
Figure 3 Charts demonstrating the trend of calorie intake changes during the study 
in supplementation and control groups.
















The findings were not in concordance with those reported 
by Kelly31 and Tavakkoli Darestani et al.32 In their studies, 
the consumption of CLA supplementation by healthy females 
did not affect the serum level of IL
1β, which might be related 
to the sample they studied. In this study, however, the use 
of CLA supplementation for 6 weeks significantly increased 
caloric intake and the absorption of macronutrients, such as 
carbohydrate, fat and protein, in the patients, which lead to 
an increase in their weight and BMI. However, the changes 
were not found to be statistically significant, one reason for 
which seems to be the limited intervention time.
Zambell et al33 realized that the consumption of CLA 
by young females for 64 days significantly increased their 
caloric intake.
Although the mechanism of action of CLA is not exactly 
known, one of the many possible mechanisms proposed in 
this regard is that, through changing the composition of cell 
membrane phospholipids, they can alter the cell membrane 
functions such as secondary messages, neurotransmitter recep-
tors, and transport proteins and inhibit the production of pre-
inflammatory cytokines.34 Changes in membrane phospholipids 
as well as the regulation of cytokines production might affect 
the synthesis of neuropeptides related to nutritional intake and 
eventually lead to the improvement of anorexia, which, in turn, 
can improve patients’ nutritional status and prevent weight loss 
that causes mortality to increase among COPD patients.35
One of the limitations of this study was the limitation 
that the researchers encountered in the process of identifying 
patients compatible with the criteria for entering this study. 
Another limitation was that, due to the lack of financial 
resources, the level of linoleic acid in the patients’ blood was 
not checked. Limitations in financial resources that did not 
allow the investigation of the levels of other effective inflam-
matory cytokines and the use of drugs for longer periods of 
time as well as the lack of similar studies about the effect of 
CLA on this disease made it impossible to compare the results 
of this study with other similar ones. Therefore, the authors had 
to refer to the studies conducted on other chronic diseases.
Conclusion
In this study, CLA supplementation, in addition to significantly 
reducing the serum level of IL
1β, increased appetite score, 
average caloric intake, and average macronutrients intake in 
COPD patients. Considering the findings of this study, it can 
be concluded that CLA supplementation increases appetite 
and nutritional intake and improves nutritional status of COPD 
patients, which, in turn, lead to decrease in malnutrition, slow 
progression of the disease, and may reduce the mortality.
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Table 4 The average amount of macroelements intake between the supplementation and control groups
Variables Measurement stage Supplementation group (n=45) Control group (n=45) P-value
Carbohydrate (g/d) at baseline 489.13±51.67 467.20±53.13 0.14
4th week 469.20±41.92 423.0±48.1 0.92
6th week 503.0±42.98 401.93±47.97 0.03a
P-value 0.03b 0.001b
Protein (g/d) at baseline 91.47±4.30 89.93±19.52 0.08
4th week 91.50±4.20 79.73±16.43 0.02a
6th week 110.50±2.80 47.33±17.17 0.01a
P-value 0.001b 0.06b
Total fat (g/d) at baseline 49.60±11.21 49.80±16.45 0.81
4th week 47.82±10.96 46.46±9.77 0.16
6th week 50.98±11.21 40.20±11.91 0.01a
P-value 0.04b 0.5
saturated fat (g/d) at baseline 9±3 11±6 0.71
4th week 10±5 10±4 0.58
6th week 12±4 9±3 0.04a
P-value 0.34 0.18
Mono unsaturated fat (g/d) at baseline 12±4 12.2±4.5 0.06
4th week 14±5 11±4 0.8
6th week 15±4 10.6±4 0.03a
P-value 0.19 0.39
Poly unsaturated fat (g/d) at baseline 6±2 6±3 0.07
4th week 6±2 5±1.7 0.49
6th week 7±3 5±2 0.02a
P-value 0.26 0.43
Cholesterol (mg/d) at baseline 198±130 172±120 0.08
4th week 234±115 145±52 0.03
6th week 274±208 131±39 0.01a
P-value 0.58 0.42
Fiber (g/d) at baseline 7±4 6±2 0.27
4th week 7±1 6±2 0.38
6th week 8±3 5±2 0.02a
P-value 0.65 0.26
Notes: aIndependent-sample t-test significant difference in the 6th week between groups due to significant changes of cholesterol intake. brepeated measures anOVa 
significant difference in the supplementation and placebo groups. Data are presented as mean ± sD.
Abbreviations: anOVa, analysis of variance; sD, standard deviation.
Table 5 The average amount of electrolytes intake (mg) in the supplementation and placebo groups
Variables Measurement stage Supplementation group (n=45) Placebo group (n=45) P-value
na at baseline 1,792±692 1,854±676 .0.05
4th week 1,619±573 1,729±573
6th week 1,694±401 1,694±401
Mg at baseline 180±87 196±87 .0.05
4th week 194±92 187±92
6th week 193±87 176±87
K at baseline 1,599±54 1,702±54 ,0.05a, ,0.05b
4th week 1,703±67 1,698±71
6th week 1,750±78 1,703±73
Ca at baseline 954±78 914±82 ,0.05a, ,0.05b
4th week 984±73 965±56
6th week 1,003±68 973±48
P at baseline 953±78 878±68 .0.05
4th week 944±71 980±67
6th week 860±68 860±54
Fe at baseline 37±4 38±4 .0.05
4th week 35±3 39±3
6th week 36±8 42±8
(Continued)





Table 6 The average amount of vitamins intake in the supplementation and placebo groups
Variables Measurement stage Supplementation group (n=45) Placebo group (n=45) P-value
VitB1 (mg) at baseline 0.98±0.87 0.78±0.77 .0.05
4th week 1.6±0.82 0.69±0.82
6th week 0.98±0.7 0.78±0.7
VitB3 (mg) at baseline 17±9 19±9 .0.05
4th week 17±9.3 19±9.3
6th week 17±8.7 18±8.7
Folate (μg) at baseline 59±54 70±54 .0.05
4th week 64±67 74±71
6th week 64±78 70±73
VitC (mg) at baseline 54±78 74±82 .0.05
4th week 84±73 91±56
6th week 87±68 93±48
VitB2 (μg) at baseline 1.6±0.32 1.4±0.32 ,0.05a, ,0.05b
4th week 1.6±0.34 1.6±0.33
6th week 1.6±0.32 1.1±0.32
VitB6 (mg) at baseline 1.3±0.32 1.4±0.32 ,0.05a, ,0.05b
4th week 1.6±0.55 1.6±0.17
6th week 1.6±0.12 1.5±0.32
VitB12 (mg) at baseline 4.3±0.7 5.7±0.4 .0.05
4th week 3.5±0.8 4.8±0.8
6th week 3.5±0.2 4.4±0.5
VitD (μg) at baseline 32±0.7 37±0.4 .0.05
4th week 38±0.8 38±0.8
6th week 39±0.8 38±0.5
Vita (μg) at baseline 459.43±52.01 460.39±62.01 .0.05
4th week 476±61.2 458±50.2
6th week 476±61.71 457±61.71
Vite (mg) at baseline 14.43±12.01 16.39±12.01 ,0.05a, ,0.05b
4th week 14.5±11.2 15.6±10.2
6th week 15.67±10.71 15.77±11.71
Beta-carotene (μg) at baseline 45.43±12.01 47.39±12.01 .0.05
4th week 47.5±11.2 48.6±10.2
6th week 42.67±10.71 45.77±11.71
Notes: aIndependent-sample t-test significant difference in the 6th week between groups. bRepeated measures ANOVA significant difference in the supplementation and 
placebo groups. Data are presented as mean ± sD. 
Abbreviations: anOVa, analysis of variance; sD, standard deviation.
Table 5 (Continued)
Variables Measurement stage Supplementation group (n=45) Placebo group (n=45) P-value
Zn at baseline 17±4 16±4 .0.05
4th week 18±7 19±7
6th week 18±8 17±8
Mn at baseline 1.3±0.7 1.7±0.4 .0.05
4th week 1.5±0.8 1.8±0.8
6th week 1.5±0.8 1.4±0.5
se at baseline 0.02±0.01 0.03±0.02 ,0.001a, ,0.05b
4th week 0.02±0.01 0.02±0.01
6th week 0.01±0.01 0.02±0.02
Cr at baseline 0.01±0.001 0.03±0.001 .0.05
4th week 0.02±0.001 0.07±0.001
6th week 0.04±0.003 0.05±0.003
Mo at baseline 45.43±12.01 47.39±12.01 .0.05
4th week 47.5±11.2 48.6±10.2
6th week 42.67±10.71 45.77±11.71
Notes: aIndependent-sample t-test significant difference in the 6th week between groups. bRepeated measures ANOVA significant difference in the supplementation and 
placebo groups. Data are presented as mean ± sD. 
Abbreviations: anOVa, analysis of variance; sD, standard deviation.
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